News & Updates

Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19

07/14/2020

Excerpt from the Press Release: “LA JOLLA, Calif., July 13, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that as reported by its partner, Biocon Limited, a clinical trial conducted in India by Biocon demonstrated that itolizumab significantly reduced mortality…

Read More

Connecting donated human lungs to pigs repaired damage to the organs, scientists report

07/13/2020

Excerpt from the article: “For people who need a lung transplant, the wait is often prolonged by the frustrating fact that most donor organs have to be discarded: Only 20% of donated lungs meet medical criteria for transplantation, translating into far fewer organs than people on waiting lists. Now, a team of researchers has shown…

Read More

Wyss Institute gets $16M to repurpose FDA-approved drugs for Covid-19

07/01/2020

Excerpt from the article: “As the scientific community races toward potential treatments for Covid-19, the respiratory illness caused by the novel coronavirus that has now killed at least 116,000 Americans, researchers at Harvard’s Wyss Institute are partnering with institutions across the U.S. on a new project using old materials. The Wyss Institute has signed a…

Read More

IncellDx Files Patent for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19 and Other Cytokine Storm Conditions

06/30/2020

Excerpt from the press release: “SAN FRANCISCO–(BUSINESS WIRE)–IncellDx announces the patent filing with the USPTO and the Pre-EUA with the FDA for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of a novel coronavirus disease 2019 (COVID-19), is now a global pandemic.…

Read More

4 Ways to Adapt your Inspection Readiness Framework in a Post COVID-19 World

06/29/2020

Excerpt from the article: “Although much has changed in the landscape of clinical trials because of COVID-19, the framework of inspection readiness planning and activities remains the same. It is however crucial to understand how the impacts of COVID-19 play a role in our preparation activities. Our recent Halloran Speaker Series, “Inspection Readiness Framework and…

Read More

DeviceTalks Weekly: Stryker CEO Kevin Lobo says medtech can increase workforce diversity

06/28/2020

Excerpt from the article: “This week’s DeviceTalks Weekly podcast episode talks with industry leaders about improving worker diversity and developing new ways to treat COVID-19 patients. Kevin Lobo, chairman and CEO of Stryker, explains how his company — and the industry group AdvaMed — has been working  to increase diversity of its workforce, particularly in…

Read More

Gilead to start trial of inhaled version of Covid-fighting remdesivir

06/27/2020

Excerpt from the article: “Gilead Sciences Inc. is prepping to launch clinical trials of an inhaled form of its Covid-19-fighting drug remdesivir, a version that could expand access to the treatment and keep less-severe patients out of hospitals. Remdesivir is the only drug granted emergency use authorization from the Food and Drug Administration against the…

Read More

Super-strong surgical tape detaches on demand

06/27/2020

Excerpt from the article: “Last year, MIT engineers developed a double-sided adhesive that could quickly and firmly stick to wet surfaces such as biological tissues. They showed that the tape could be used to seal up rips and tears in lungs and intestines within seconds, or to affix implants and other medical devices to the…

Read More

SFA Therapeutics Receives Grant For Drug for Acute Respiratory Distress Syndrome In COVID-19

06/26/2020

Excerpt from the press release: “PHILADELPHIA – June 24, 2020 – PRLog — SFA Therapeutics, Inc. is pleased to announce receipt of a “Save Our Start-ups” (SOS) grant to study SFA005 in the treatment of cytokine storm linked to Acute Respiratory Distress Syndrome (ARDS), which has been experienced by patients infected with COVID-19. This grant…

Read More

Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 Patients

06/25/2020

Excerpt from the press release: “CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it received early notification from the U.S. Food and Drug Administration (FDA) that the company may proceed with initiating…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives